Supplementary Table 3 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma

Supplementary Table 3 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma

<p>Supplementary Table 3 Uni- and multivariate Cox survival analysis using HJURP and NSD2 expression in myeloma dataset</p>

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awdur:	Yunlu Jia (2012017) (author)
Awduron Eraill:	Jianbiao Zhou (14935538) (author), Tze King Tan (15203447) (author), Tae-Hoon Chung (4343) (author), Yongxia Chen (424187) (author), Jing-Yuan Chooi (4238347) (author), Takaomi Sanda (15203450) (author), Melissa J. Fullwood (14195681) (author), Sinan Xiong (6175022) (author), Sabrina H.M. Toh (15203453) (author), Kalpnaa Balan (15203456) (author), Regina W.J. Wong (15203459) (author), Julia S.L. Lim (14935541) (author), Enfan Zhang (9965455) (author), Zhen Cai (576458) (author), Peng Shen (688111) (author), Wee Joo Chng (14959944) (author)
Cyhoeddwyd:	2025
Pynciau:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Mechanisms of transcription Hematological Cancers Myelomas Oncogenes & Tumor Suppressors Oncogenes
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg

Supplementary Table 1 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
gan: Yunlu Jia (2012017)
Cyhoeddwyd: (2025)

Supplementary Table 2 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
gan: Yunlu Jia (2012017)
Cyhoeddwyd: (2025)

Supplementary Table 5 from Super Enhancer-Mediated Upregulation of <i>HJURP</i> Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
gan: Yunlu Jia (2012017)
Cyhoeddwyd: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
gan: Smruthy Sivakumar (15053536)
Cyhoeddwyd: (2025)

Table S1 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
gan: Lijun Yao (15292963)
Cyhoeddwyd: (2025)

Table S2 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
gan: Lijun Yao (15292963)
Cyhoeddwyd: (2025)

Table S3 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
gan: Lijun Yao (15292963)
Cyhoeddwyd: (2025)

Table S4 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
gan: Lijun Yao (15292963)
Cyhoeddwyd: (2025)

Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
gan: Lijun Yao (15292963)
Cyhoeddwyd: (2025)

Table S6 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
gan: Lijun Yao (15292963)
Cyhoeddwyd: (2025)

Supplementary Data S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
gan: Keiji Kurata (15055090)
Cyhoeddwyd: (2025)

Supplementary Data S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
gan: Keiji Kurata (15055090)
Cyhoeddwyd: (2025)

Supplementary Data S3 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
gan: Keiji Kurata (15055090)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S1 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S10 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S11 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S12 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S2 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S3 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S4 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S5 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S6 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S7 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S8 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Supplementary Spreadsheet S9 from Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma
gan: Eileen M. Boyle (15015425)
Cyhoeddwyd: (2025)

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
gan: Kazuhito Suzuki (22688384)
Cyhoeddwyd: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
gan: Feng Wang (44414)
Cyhoeddwyd: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
gan: Feng Wang (44414)
Cyhoeddwyd: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
gan: Feng Wang (44414)
Cyhoeddwyd: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
gan: Feng Wang (44414)
Cyhoeddwyd: (2025)

Supplementary Movie 1 from The Macrophage-Associated LncRNA <i>MALR</i> Facilitates ILF3 Liquid–Liquid Phase Separation to Promote HIF1α Signaling in Esophageal Cancer
gan: Jia Liu (15386858)
Cyhoeddwyd: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Cannot write session to /tmp/vufind_sessions/sess_bd0nba996th4uanorg5s33m18f